Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M
Kleiner Perkins is joining the syndicate backing Penn spinout Tmunity, adding $35 million for the cell therapy cause and bringing its launch round to a mammoth $135 million.
General Partner and longtime life sciences investor Beth Seidenberg is handling the investment for the high-profile venture group. And she’s not at all new to this.
Seidenberg also invested in Cell Design Labs, a company that was advancing a next-gen approach to CAR-T under UCSF scientist Wendell Lim, which Gilead snapped up a few months ago in a deal worth up to $567 million in the wake of its $12 billion Kite buyout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.